as of 09-04-2026 3:46pm EST
Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.
| Founded: | N/A | Country: | N/A |
| Employees: | N/A | City: | TALLAHASSEE |
| Market Cap: | 1.7B | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | 26.58 |
| 52 Week Low/High: | $7.82 - $12.28 | Next Earning Date: | N/A |
| Revenue: | $1,181,180,000 | Revenue Growth: | -0.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -20.76 | Index: | N/A |
| Free Cash Flow: | 228.6M | FCF Growth: | N/A |
SEC 8-K filings with transcript text
May 7, 2026
2 exhibit991tcnnfearningsrel.htm
Document
Exhibit 99.1
Trulieve Reports Profitable First Quarter 2026 Results
Bolstered by Margins and Cash Flow Generation
•First quarter revenue of $287 million, with 59% gross margin
•Positive net income of $2 million and Adjusted EBITDA of $100 million*
•Rescheduling of medical marijuana to Schedule III enabled applications for DEA registration
Tallahassee, FL – May 7, 2026 – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended March 31, 2026. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.
Q1 2026 Financial and Operational Highlights*
•Revenue of $287 million, with 92% of revenue from retail sales.
•Achieved gross margin of 59%, with GAAP gross profit of $170 million.
•Reported positive net income attributable to common shareholders of $2 million. Adjusted net income of $20 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
•Achieved adjusted EBITDA of $100 million*, or 35% of revenue.
•Generated cash flow from operations of $56 million and free cash flow of $42 million*.
•Cash at quarter end was $353 million.
•Closed $60 million private placement of senior secured notes due 2030.
•Grew rewards program to 1 million members.
•Opened three dispensaries in DeLand, Fort Myers, and Lake Wales, Florida.
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Recent Developments
•The Trump Administration reclassified medical marijuana to Schedule III under the Controlled Substances Act. Attorney General Blanche announced an expedited process to review the classification of marijuana more broadly with a hearing beginning on June 29, 2026.
•Filed applications to register state licensed medical marijuana operations including 206 retail locations with the Drug Enforcement Agency.
•Opened four dispensaries in Belleview, Boca Raton, Lutz, and Tallahassee, Florida.
•Currently operate 240 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.
Management Commentary
“We applaud President Trump and AG Blanche for taking bold, decisive action to reclassify medical marijuana to Schedule III,” said Kim Rivers, Trulieve CEO. “With 206 dispensaries and over 3.5 million square feet of production serving medical patients, Trulieve is well positioned to explore new opportunities enabled by rescheduling.”
Financial Highlights*
Results of OperationsFor the Three Months Ended
(Figures in millions except per share data) March 31, 2026March 31, 2025% Better / (Worse)December 31, 2025% Better / (Worse)
Revenue$287$298(4%)$293(2%)
Gross profit$170$183(7%)$175(3%)
Gross margin %59%62%60%
Operating expenses$134$15010%$16016%
Operating expenses %47%50%55%
Net income (loss)**$2$(33)NMF$(43)NMF
Net income (loss) continuing operations$3$(32)NMF$(45)NMF
Adjusted net income (loss)$20$(3)NMF$(3)NMF
Diluted shares outstanding198191192
Diluted EPS continuing operations$0.02$(0.16)NMF$(0.23)NMF
Adjusted Diluted EPS$0.10$(0.02)NMF$(0.02)NMF
Adjusted EBITDA$100$109(8%)$105(4%)
Adjusted EBITDA Margin %35%37%36%
NMF - No Meaningful Figure
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
**Net income (loss) attributable to common shareholders which excludes non-controlling interest.
Conference Call
The Company will host a conference call and live audio webcast on May 7, 2026, at 8:30 A.M. Eastern time, to discuss its first quarter 2026 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.
North American toll free: 1-844-824-3830Passcode: 0642610
International: 1-412-542-4136Passcode: 0642610
A live audio webcast of the conference call will be available at:
Trulieve First Quarter 2026 Results Call
A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events
The Company’s Form 10-Q for the quarter ended March 31, 2026 will be available on the SEC’s website or at https://investors.trulieve.com/quarterly-results. The Company’s Management's Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company’s profile on https://www.sedarplus.ca and on its website at https://investors.trulieve.com/quarterly-results. This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.
Trulieve Cannabis Corp.
Condensed Consolidated Balance Sheets (Unaudited)
(in m
Feb 26, 2026
2 exhibit991tcnnfearningsrel.htm
Document
Exhibit 99.1
Trulieve Reports Fourth Quarter and Full Year 2025 Results with
60% Gross Margin and Record Cash Flow Generation
•Full year revenue of $1.2 billion, with 60% gross margin
•Record 2025 cash flow from operations of $273 million and free cash flow of $229 million*
•Record 50.1 million branded product units sold in 2025, up 5% compared to last year
Tallahassee, FL – February 26, 2026 – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced its results for the fourth quarter and full year ended December 31, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.
2025 Full Year Financial and Operational Highlights*
•Revenue of $1.2 billion, with 94% of revenue from retail sales.
•Achieved gross margin of 60%, with GAAP gross profit of $711 million.
•Reported net loss attributable to common shareholders of $116 million. Adjusted net loss of $27 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
•Achieved record adjusted EBITDA of $427 million*, or 36% of revenue, up $7 million or 2% from 2024.
•Generated record cash flow from operations of $273 million and free cash flow of $229 million*.
•Cash at year end totaled $256 million.
•Redeemed $368 million of senior secured notes due 2026 and repaid $15.8 million mortgage.
•Closed $140 million private placement of senior secured notes due 2030.
•Granted conditional approval for a Dispensing Organization license under the Texas Compassionate Use Program.
•Grew rewards program to 915,000 members as of December 31, 2025.
•Added 11 dispensaries in 2025, with 233 retail locations nationwide at year end.
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Q4 2025 Financial and Operational Highlights*
•Revenue of $293 million, with 93% of revenue from retail sales.
•Achieved gross margin of 60%, with GAAP gross profit of $175 million.
•Reported net loss attributable to common shareholders of $43 million. Adjusted net loss of $3 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
•Achieved adjusted EBITDA of $105 million*, or 36% of revenue.
•Generated cash flow from operations of $59 million and free cash flow of $56 million*.
•Released a new mobile app serving Florida customers enabling patients to browse and reserve products, view promotions, and check rewards status through a seamless digital experience.
•Opened one dispensary in Findlay, Ohio.
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Recent Developments
•Opened one dispensary in Fort Myers, Florida.
•Closed second tranche $60 million private placement of senior secured notes due 2030.
•Currently operate 234 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.
Management Commentary
“We finished the year strong, winning a conditional license in Texas and repositioning our debt,” said Kim Rivers, Trulieve CEO. “With rescheduling on the horizon, Trulieve is carrying the momentum into 2026, prioritizing expanded access, loyal customers, branded products and growth initiatives.”
Financial Highlights*
Results of OperationsFor the Three Months EndedFor the Full Year Ended
(Figures in millions except per share data) December 31, 2025December 31, 2024% Better / (Worse)September 30, 2025% Better / (Worse)December 31, 2025December 31, 2024% Better / (Worse)
Revenue$293$301(3%)$2882%$1,181$1,186—%
Gross profit$175$187(6%)$1703%$711$716(1%)
Gross margin %60%62%59%60%60%
Operating expenses$160$18614%$128(25%)$568$6188%
Operating expenses %55%62%44%48%52%
Net loss**$(43)$(60)28%$(27)(60%)$(116)$(155)25%
Net loss continuing operations$(45)$(60)26%$(24)(89%)$(117)$(155)25%
Adjusted net (loss) income$(3)$3NMF$(12)75%$(27)$(19)(41%)
Basic and diluted shares outstanding192190191191190
EPS continuing operations$(0.23)$(0.26)12%$(0.11)(103%)$(0.58)$(0.79)26%
Adjusted EPS$(0.02)$0.02NMF$(0.07)75%$(0.14)$(0.10)(40%)
Adjusted EBITDA$105$111(6%)$1032%$427$4202%
Adjusted EBITDA Margin %36%37%36%36%35%
NMF - No Meaningful Figure
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
**Net loss attributable to common shareholders which excludes non-controlling interest.
Conference Call
The Company will host a conference call and live audio webcast on February 26, 2026, at 8:30 A.M. Eastern time, to discuss its fourth quarter and full year 2025 financial results. Interested parties can join the conference call by dialing
Nov 5, 2025
2 exhibit991tcnnfearningsrel.htm
Document
Exhibit 99.1
Trulieve Reports Third Quarter 2025 Results Demonstrating
Operational Discipline and Cash Flow Strength
•Third quarter revenue of $288 million, with 59% gross margin
•Year to date cash flow from operations of $214 million and free cash flow of $173 million*
•Sold over 12.5 million branded products in the third quarter, up 7% compared to last year
Tallahassee, FL – November 5, 2025 – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended September 30, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.
Q3 2025 Financial and Operational Highlights*
•Revenue of $288 million, with 94% of revenue from retail sales.
•Achieved gross margin of 59%, with GAAP gross profit of $170 million.
•Reported net loss attributable to common shareholders of $27 million. Adjusted net loss of $12 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
•Achieved adjusted EBITDA of $103 million*, or 36% of revenue, up 7% year over year.
•Generated cash flow from operations of $77 million and free cash flow of $64 million*.
•Cash at quarter end was $458 million.
•Added Chief Financial Officer Jan Reese to the leadership team and appointed Matthew Foulston to the Board of Directors.
•Rewards program members reached 820,000 members as of September 30, 2025. Loyalty members accounted for 77% of transactions during the third quarter.
•Launched new Roll One Clutch All In One vapes in Florida, selling out in under two weeks.
•Expanded distribution of Onward premium THC beverages in Florida and Illinois, launched new Upward THC energy drinks, and introduced five new 10mg flavors.
•Opened one dispensary in Cincinnati, Ohio and relocated one dispensary to Bisbee, Arizona.
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Recent Developments
•Announced planned redemption of $368 million of senior secured notes due 2026.
•Launched new mobile app serving Florida customers enabling patients to browse and reserve products, view promotions, and check rewards status through a seamless digital experience.
•Currently operate 232 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.
Management Commentary
“Our 2025 strategic plan is delivering results, with demonstrable progress on reform, customers, distribution, and branded products,” said Kim Rivers, Trulieve CEO. “Significant flexibility in our core business and strong cash generation continue to set us apart in a dynamic market.”
Financial Highlights*
Results of OperationsFor the Three Months EndedFor the Nine Months Ended
(Figures in millions except per share data) September 30, 2025September 30, 2024% Better / (Worse)June 30, 2025% Better / (Worse)September 30, 2025September 30, 2024% Better / (Worse)
Revenue$288$2841%$302(5%)$888$885—%
Gross profit$170$173(2%)$183(7%)$536$5291%
Gross margin %59%61%61%60%60%
Operating expenses$128$17326%$1302%$408$4326%
Operating expenses %44%61%43%46%49%
Net loss**$(27)$(60)55%$(14)(95%)$(73)$(95)23%
Net loss continuing operations$(24)$(60)61%$(16)(50%)$(72)$(94)24%
Adjusted net (loss) income$(12)$(12)(5%)$(8)(61%)$(24)$(22)(8%)
Basic and diluted shares outstanding191190191191190
EPS continuing operations$(0.11)$(0.32)64%$(0.07)(62%)$(0.35)$(0.52)34%
Adjusted EPS$(0.07)$(0.06)(5%)$(0.04)(61%)$(0.12)$(0.12)(7%)
Adjusted EBITDA$103$967%$111(7%)$322$3094%
Adjusted EBITDA Margin %36%34%37%36%35%
*See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
**Net loss attributable to common shareholders which excludes non-controlling interest.
Conference Call
The Company will host a conference call and live audio webcast on November 5, 2025, at 8:30 A.M. Eastern time, to discuss its third quarter 2025 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.
North American toll free: 1-844-824-3830Passcode: 9870622
International: 1-412-542-4136Passcode: 9870622
A live audio webcast of the conference call will be available at:
Trulieve Third Quarter 2025 Results Call
A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events
The Company’s Form 10-Q for the quarter ended September 30, 2025 will be available on the SEC’s website or at https://investors.trulieve.com/quarterly-results. The Company’s Management's Discussion and Analysis for the period and the accompanying financial statements an
See how TRLV stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TRLV Trulieve Cannabis Corp. Subordinate Voting Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.